NASDAQ:RCKT Rocket Pharmaceuticals Q4 2024 Earnings Results & Report $2.39 -0.09 (-3.63%) Closing price 04:00 PM EasternExtended Trading$2.37 -0.02 (-0.84%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Rocket Pharmaceuticals beat analyst earnings expectations in its Q4 2024 results, released March 3, 2025. The company reported EPS of -$0.62 versus the -$0.68 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateMarch 3, 2025TimeBefore Market OpensConference Call DateFebruary 27, 2025Conference Call4:00 PM ET Rocket Pharmaceuticals EPS ResultsActual EPS-$0.62Consensus EPS -$0.68Beat/MissBeat by +$0.06One Year Ago EPSN/AEPS Beat Rate6 of last 8 quartersRocket Pharmaceuticals Revenue ResultsActual RevenueN/AExpected Revenue$31 thousandBeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsRocket Pharmaceuticals' Q4 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedulesConference Call ResourcesReportAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsReportAnnual report(10-K) Rocket Pharmaceuticals Q4 2024 Earnings FAQ Did Rocket Pharmaceuticals beat earnings estimates for Q4 2024? Rocket Pharmaceuticals (NASDAQ:RCKT) reported earnings of -$0.62 per share for Q4 2024, beating the consensus estimate of -$0.68. The report was announced on Monday, March 3, 2025. When is Rocket Pharmaceuticals' next earnings date? Rocket Pharmaceuticals' next earnings date is estimated for Thursday, November 12, 2026. MarketBeat tracks confirmed and estimated earnings dates for Rocket Pharmaceuticals on the company's earnings history page. Rocket Pharmaceuticals Earnings HeadlinesRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Stock Now Rated "Hold" by Wall Street BrokeragesNovember 4, 2026 | americanbankingnews.comRocket Pharmaceuticals Inc (RCKT)October 9, 2026 | za.investing.comI'm handing you this stock todayElon doesn't own the chip inside his Teslas or Starlink dishes. He licenses it from one little known public company. Now he's planning 1,000,000 AI satellites in orbit, and every one could pay this company a royalty. Analyst Dylan says the window to get in closes around December 8th, before new money floods into the buildout.November 12 at 1:00 AM | Behind the Markets (Ad)Analysts Are Bullish on These Healthcare Stocks: Viking Therapeutics (VKTX), Rocket Pharmaceuticals (RCKT)October 9, 2026 | theglobeandmail.comRocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facilityOctober 7, 2026 | proactiveinvestors.comRocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor WebinarOctober 7, 2026 | businesswire.comSee More Rocket Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Rocket Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Rocket Pharmaceuticals and other key companies, straight to your email. Email Address About Rocket PharmaceuticalsRocket Pharmaceuticals (NASDAQ:RCKT) is a biotechnology company developing gene therapies for rare, serious diseases, with a focus on inherited disorders that often affect children. Its research programs use lentiviral and adeno-associated viral (AAV) vector technologies to deliver therapeutic genes to patients’ cells. The company’s pipeline has included programs targeting conditions such as Fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, Danon disease and arrhythmogenic cardiomyopathy. Rocket conducts research and clinical development from its base in Cranbury, New Jersey, and works to advance its therapies through clinical testing and regulatory review.View Rocket Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-OffSix Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping3 Pharmaceutical Stocks That Offer Safety and GrowthKeeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCoreWeave's Backlog Is Surging—Can the Stock Follow?Can Constellation Energy's Contracts Power a Stock Rebound? Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
